For the Inventor, By the Inventor

Enter assignee name

Den Bosch, Netherlands

Pamgene Bv

Calculating rank

USPTO Granted Patents = 17

% Expired Patents = 47.1

EPO Patents = 17

Trademarks = 1

Forward Citations = 81

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Robby Ruijtenbeek (8 out of 9 patents)

Richard De Wijn (5 out of 5 patents)

Maria Helena Hilhorst (3 out of 4 patents)

4. Marinus Gerardus Johannes Van Beuningen (2 out of 2 patents)

5. Pieter Jacob Boender (2 out of 4 patents)

6. Hendrik Sibolt Van Damme (2 out of 5 patents)

7. Wilhemus M Carpay (2 out of 2 patents)

8. Roeland F Papen (2 out of 13 patents)

9. Dirgje Maria Adriana Van Den Heuvel (2 out of 2 patents)

10. Liesbeth Coosje Hovestad-Bijl (1 out of 1 patent)

11. Hermanus Johannes Maria Kreuwel (1 out of 10 patents)

12. Jeroen Van Ameijde (1 out of 1 patent)

13. Robertus Matthias Joseph Liskamp (1 out of 2 patents)

14. René Houtman (1 out of 1 patent)

15. Arzu Umar (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 12624383 - KINASE ACTIVITY SIGNATURES FOR PREDICTING THE RESPONSE OF NON-SMALL-CELL LUNG CARCINOMA PATIENTS TO A PD-1 OR PD-L1 IMMUNE CHECKPOINT INHIBITOR (2026-05-12),

2. 11802315 - Method for predicting the response of non-small-cell lung carcinoma patients to a medicament (2023-10-31),

3. 10604786 - Method for predicting the response of melanoma patients to targeted pharmacotherapy (2020-03-31),

4. 9448237 - Modified tyrosine amino acids, peptides containing them, and their use for detecting hydrolase enzyme activity (2016-09-20),

5. 9128087 - Nuclear receptor assay (2015-09-08),

6. 9075061 - Method for determining the estrogen receptor status of breast cancer (2015-07-07),

7. 8962268 - Method for determining survival prognosis of patients suffering from non-small cell lung cancer (NSCLC) (2015-02-24),

8. 8962267 - Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy (2015-02-24),

9. 8617836 - Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy (2013-12-31),

10. 7504209 - Method and device for integrated nucleic acid integrity assessment and analysis (2009-03-17),

11. 7473562 - Method for high-throughput integrated chemical and biochemical reactions (2009-01-06),

12. 7364848 - Integrated microarray analysis (2008-04-29),

13. 7105134 - Device for holding a substrate (2006-09-12),

14. 6849408 - Analytical test device with substrate having oriented through going channels and improved methods and apparatus for using same (2005-02-01),

15. 6635493 - Device for performing an assay, a method for manufacturing said device, and use of a membrane in the manufacture of said device (2003-10-21),

Company Overview

Pamgene Bv, based in Den Bosch, Netherlands, specializes in advanced technologies for biomarker discovery and validation. The company focuses on developing innovative solutions for high-throughput screening and analysis, particularly in the fields of personalized medicine and oncology. By leveraging proprietary platforms, Pamgene aims to enhance drug development processes and improve patient outcomes through precise molecular insights. Their expertise lies in integrating cutting-edge science with practical applications in the life sciences sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

17 Patents

#5 in Den Bosch

#406 in Netherlands

#35,974 in the World

Den Bosch, Netherlands

Pamgene Bv

Forward Citations = 81

30 inventors:

Robby Ruijtenbeek (8 out of 9 patents)

Richard De Wijn (5 out of 5 patents)

Maria Helena Hilhorst (3 out of 4 patents)

4. Marinus Gerardus Johannes Van Beuningen (2 out of 2 patents)

5. Pieter Jacob Boender (2 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pamgene Bv. Retrieved from https://idiyas.com/company/pamgene-bv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…